Designed recombinant adenovirus type 5 vector induced envelope‐specific CD8+ cytotoxic T lymphocytes and cross‐reactive neutralizing antibodies against human immunodeficiency virus type 1
- 8 December 2008
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 11 (2) , 139-149
Abstract
Background: A monoclonal antibody (mAb) 2F5 binds to the membrane‐proximal external region (MPER) of the transmembrane subunit gp41 of human immunodeficiency virus type 1 (HIV‐1) is known to broadly neutralize HIV‐1 strains. The Adenovirus type 5 vector (Ad5) has been widely applied for HIV‐1 vaccine, and hexon hypervariable region 5 (HVR5) is exposed on viral surface and easily target host immune responses against Ad5.Methods: We constructed a recombinant adenovirus type 5 vector (rAd5) with a 2F5‐binding epitope (ELDKWA) of MPER on Ad5‐HVR5. In addition, we developed rAd5 encoding the HIV‐1IIIB envelope (Env) gene for the induction of Env‐specific cellular immunity.Results: The virus titers of the constructed rAd5 were similar to that of the parental Ad5 vector. Furthermore, high‐dose immunization of rAd5 induced Env‐specific CD8+ cells and high levels of anti‐ELDKWA antibodies. Moreover, an in vitro HIV‐1 neutralization assay indicated that ELDKWA‐specific mAbs derived from rAd5‐immunized mice neutralized a wide range of HIV‐1 strains.Conclusions: The present study outlines the development of an Ad5‐based HIV‐1 vaccine targeting the hypervariable regions of Ad5. The constructed rAd5 induced an HIV‐1‐specific cellular immune response and neutralizing antibodies against various strains of HIV‐1 simultaneously. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 64 references indexed in Scilit:
- Functional Links between the Fusion Peptide-proximal Polar Segment and Membrane-proximal Region of Human Immunodeficiency Virus gp41 in Distinct Phases of Membrane FusionJournal of Biological Chemistry, 2007
- Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesNature Medicine, 2005
- Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 EpitopeJournal of Virology, 2004
- Urgently needed: a filter for the HIV-1 vaccine pipelineNature Medicine, 2004
- Human Immunodeficiency Virus Type 1-neutralizing Monoclonal Antibody 2F5 is Multispecific for Sequences Flanking the DKW Core EpitopeJournal of Molecular Biology, 2004
- HIV vaccine design and the neutralizing antibody problemNature Immunology, 2004
- HIV vaccines 1983–2003Nature Medicine, 2003
- The structural biology of type I viral membrane fusionNature Reviews Molecular Cell Biology, 2003
- A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1994
- Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.Proceedings of the National Academy of Sciences, 1994